Fig. 2.

Dose-related effects of SK-1202 on spontaneous bowel movements (SBMs) in patients with chronic constipation. a Changes in SBMs from baseline at Week 1. b Change in SBMs from baseline at Week 2. c Percentage of patients who had initial SBM within 24 or 48 h after initiation of SK-1202 treatment. The columns and bars represent mean ± standard deviation in a and b. The columns and numbers represent mean of percentage of patients in c. Significant differences in changes in SBMs from baseline based on ANCOVA with average weekly SBMs at baseline as covariate: *p < 0.05, **p < 0.01, ***p < 0.001 vs. placebo. Significant differences in the percentage of patients with initial SBM based on Fisher’s Exact Test, ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 vs placebo